Drug intelligence / Profile preview

PS386113

Development stage: Discontinued
Lead developer: Merck
Modality: Small Molecules
Administration: Oral (inferred Based On Typical Administration Route For Small Molecules In Early Phase Trials; Not Explicitly Stated)

Overview

PS386113 is a small molecule drug candidate that was developed for the treatment of inflammatory disorders. It originated from a collaboration between Pharmacopeia and Schering-Plough, with initial development by Ligand Pharmaceuticals. The compound entered Phase 1 clinical trials as a potential therapy for inflammatory diseases but was later discontinued in development. The specific mechanism of action and molecular targets have not been publicly disclosed[1][2][3][5][7].

Beyond the preview

Go deeper on PS386113.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PS386113.

Explore the full profile